Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVDL NASDAQ:CKPT NASDAQ:HROW NASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$15.81+1.4%$12.40$6.38▼$16.66$1.51B1.581.37 million shs1.63 million shsCKPTCheckpoint Therapeutics$4.26$4.23$2.06▼$4.50$370.71M1.181.56 million shsN/AHROWHarrow$38.87-1.1%$35.81$20.85▼$59.23$1.45B0.33540,726 shs443,071 shsSDGRSchrodinger$18.15-6.7%$20.31$16.60▼$28.47$1.43B1.791.15 million shs1.36 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals+1.41%+7.84%+23.61%+69.27%+9.87%CKPTCheckpoint Therapeutics0.00%0.00%0.00%0.00%+99.07%HROWHarrow-1.09%+4.10%+15.20%+24.74%-5.33%SDGRSchrodinger-6.73%-5.91%-2.58%-20.50%-10.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$15.81+1.4%$12.40$6.38▼$16.66$1.51B1.581.37 million shs1.63 million shsCKPTCheckpoint Therapeutics$4.26$4.23$2.06▼$4.50$370.71M1.181.56 million shsN/AHROWHarrow$38.87-1.1%$35.81$20.85▼$59.23$1.45B0.33540,726 shs443,071 shsSDGRSchrodinger$18.15-6.7%$20.31$16.60▼$28.47$1.43B1.791.15 million shs1.36 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals+1.41%+7.84%+23.61%+69.27%+9.87%CKPTCheckpoint Therapeutics0.00%0.00%0.00%0.00%+99.07%HROWHarrow-1.09%+4.10%+15.20%+24.74%-5.33%SDGRSchrodinger-6.73%-5.91%-2.58%-20.50%-10.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVDLAvadel Pharmaceuticals 3.11Buy$20.8631.92% UpsideCKPTCheckpoint Therapeutics 2.33Hold$4.331.72% UpsideHROWHarrow 3.13Buy$64.6766.37% UpsideSDGRSchrodinger 2.67Moderate Buy$27.8353.35% UpsideCurrent Analyst Ratings BreakdownLatest CKPT, HROW, SDGR, and AVDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$24.00 ➝ $36.009/3/2025AVDLAvadel PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/3/2025AVDLAvadel PharmaceuticalsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/2/2025AVDLAvadel PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageEqual Weight$16.008/21/2025AVDLAvadel PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $20.008/18/2025SDGRSchrodingerMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$28.00 ➝ $19.008/15/2025SDGRSchrodingerCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $20.008/14/2025SDGRSchrodingerBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$25.008/14/2025HROWHarrowZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/14/2025HROWHarrowBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$62.00 ➝ $63.008/14/2025SDGRSchrodingerBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$25.00(Data available from 9/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVDLAvadel Pharmaceuticals$169.12M9.08N/AN/A$0.77 per share20.53CKPTCheckpoint Therapeutics$41K9,041.59N/AN/A($0.47) per share-9.06HROWHarrow$199.61M7.20$0.14 per share287.40$1.95 per share19.93SDGRSchrodinger$207.54M6.44N/AN/A$5.78 per share3.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVDLAvadel Pharmaceuticals-$48.83M-$0.03N/A263.50N/A-1.32%-3.73%-1.73%11/11/2025 (Estimated)CKPTCheckpoint Therapeutics-$51.85M-$1.29N/A∞N/AN/AN/A-659.07%N/AHROWHarrow-$17.48M-$0.25N/A97.18N/A-4.49%-2.18%-0.35%11/12/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.48N/AN/AN/A-76.22%-45.70%-24.81%11/11/2025 (Estimated)Latest CKPT, HROW, SDGR, and AVDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025HROWHarrow$0.01$0.24+$0.23$0.13$64.23 million$63.74 million8/7/2025Q2 2025AVDLAvadel Pharmaceuticals$0.02$0.10+$0.08$0.10$60.28 million$68.13 million8/6/2025Q2 2025SDGRSchrodinger-$0.83-$0.59+$0.24-$0.59$52.03 million$54.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ACKPTCheckpoint TherapeuticsN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVDLAvadel PharmaceuticalsN/A2.792.38CKPTCheckpoint TherapeuticsN/A0.290.29HROWHarrow0.780.620.58SDGRSchrodingerN/A3.303.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVDLAvadel Pharmaceuticals69.19%CKPTCheckpoint Therapeutics22.00%HROWHarrow72.76%SDGRSchrodinger79.05%Insider OwnershipCompanyInsider OwnershipAVDLAvadel Pharmaceuticals5.20%CKPTCheckpoint Therapeutics2.10%HROWHarrow15.16%SDGRSchrodinger21.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVDLAvadel Pharmaceuticals7097.10 million92.05 millionOptionableCKPTCheckpoint Therapeutics1087.02 million47.81 millionOptionableHROWHarrow18037.00 million31.39 millionOptionableSDGRSchrodinger79073.61 million58.15 millionOptionableCKPT, HROW, SDGR, and AVDL HeadlinesRecent News About These CompaniesSchrodinger, Inc. (NASDAQ:SDGR) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 10 at 3:12 AM | marketbeat.comDoes Schrodinger (SDGR) Have the Potential to Rally 40.43% as Wall Street Analysts Expect?September 9 at 10:55 AM | zacks.comSchrödinger, Inc. (SDGR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 8 at 8:20 PM | seekingalpha.comSchrodinger Announces CFO Geoffrey Porges’ DepartureSeptember 8 at 8:20 PM | msn.comParkman Healthcare Partners LLC Reduces Holdings in Schrodinger, Inc. $SDGRSeptember 8 at 7:45 AM | marketbeat.comSchrodinger, Inc. $SDGR Shares Sold by Northern Trust CorpSeptember 7, 2025 | marketbeat.comRussell Investments Group Ltd. Reduces Stock Position in Schrodinger, Inc. $SDGRSeptember 2, 2025 | marketbeat.comKodai Capital Management LP Makes New $3.03 Million Investment in Schrodinger, Inc. $SDGRSeptember 1, 2025 | marketbeat.comSchrodinger (NASDAQ:SDGR) Downgraded to "Sell" Rating by Wall Street ZenSeptember 1, 2025 | marketbeat.comTema Etfs LLC Sells 18,331 Shares of Schrodinger, Inc. $SDGRAugust 31, 2025 | marketbeat.comNuveen LLC Makes New $2.87 Million Investment in Schrodinger, Inc. $SDGRAugust 31, 2025 | marketbeat.comAlphaQuest LLC Trims Holdings in Schrodinger, Inc. $SDGRAugust 29, 2025 | marketbeat.comDeutsche Bank AG Sells 188,717 Shares of Schrodinger, Inc. $SDGRAugust 27, 2025 | marketbeat.comAmerican Century Companies Inc. Invests $19.79 Million in Schrodinger, Inc. $SDGRAugust 26, 2025 | marketbeat.comSchrodinger, Inc. $SDGR Shares Sold by Vanguard Group Inc.August 24, 2025 | marketbeat.comSchrödinger: A Complex Story With Many Moving PartsAugust 21, 2025 | seekingalpha.comPublic Sector Pension Investment Board Raises Stake in Schrodinger, Inc. $SDGRAugust 21, 2025 | marketbeat.comCetera Investment Advisers Takes Position in Schrodinger, Inc. $SDGRAugust 21, 2025 | marketbeat.comMorgan Stanley Cuts Schrodinger (NASDAQ:SDGR) Price Target to $19.00August 20, 2025 | marketbeat.comWhat 4 Analyst Ratings Have To Say About SchrodingerAugust 18, 2025 | benzinga.comTocqueville Asset Management L.P. Sells 23,590 Shares of Schrodinger, Inc. (NASDAQ:SDGR)August 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCKPT, HROW, SDGR, and AVDL Company DescriptionsAvadel Pharmaceuticals NASDAQ:AVDL$15.81 +0.22 (+1.41%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$15.88 +0.07 (+0.47%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Checkpoint Therapeutics NASDAQ:CKPTCheckpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.Harrow NASDAQ:HROW$38.87 -0.43 (-1.09%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$38.75 -0.12 (-0.31%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Schrodinger NASDAQ:SDGR$18.15 -1.31 (-6.73%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$18.27 +0.12 (+0.66%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
